High-grade gliomas

Current Treatment Options in Neurology

Volumn 13, Issue 4, 2011, Pages 386-399

  Theeler, Brett J ^b   Groves, Morris D ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CARMUSTINE; CEDIRANIB; CILENGITIDE; ERLOTINIB; ETOPOSIDE; IRINOTECAN; LOMUSTINE; NITROSOUREA; PROCARBAZINE; PROTEIN TYROSINE KINASE; TALAMPANEL; TEMOZOLOMIDE; VALPROIC ACID; VINCRISTINE;

ARTICLE; ASTROCYTOMA; BLEEDING; BONE MARROW SUPPRESSION; BRAIN DISEASE; CANCER GRADING; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CENTRAL NERVOUS SYSTEM DEPRESSION; COLORECTAL CANCER; CONSTIPATION; DIGESTIVE SYSTEM PERFORATION; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; EPENDYMOMA; FATIGUE; GLIOBLASTOMA; GLIOMA; HAIR LOSS; HEADACHE; HUMAN; HYPERTENSION; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; METASTASIS; MOLECULAR PATHOLOGY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROIMAGING; NEUROPATHY; OLIGODENDROGLIOMA; OPTIMAL DRUG DOSE; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEIN TARGETING; PROTEINURIA; RECURRENT CANCER; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS; VOMITING; WOUND HEALING IMPAIRMENT;

EID: 80051666626     PISSN: 10928480     EISSN: 15343138     Source Type: Journal    
DOI: 10.1007/s11940-011-0130-0     Document Type: Article

References (50)

1. CBTRUS. CBTRUS Statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2004-2006. Source: Central Brain Tumor Registry of the United States, Hinsdale, IL; 2010. Available at http://www.cbtrus.org/2010-NPCR-SEER/CBTRUS-WEBREPORT-Final-3-2-10.pdf. Accessed September 2010.
2. DN Louis H Ohgaki OD Wiestler, et al. 2007 The 2007 WHO classification of tumors of the central nervous system Acta Neuropathol 114 2 97 109 17618441 10.1007/s00401-007-0243-4 (Pubitemid 47103521)
3. PY Wen S Kesari 2008 Malignant gliomas in adults N Engl J Med 359 5 492 507 18669428 10.1056/NEJMra0708126 1:CAS:528:DC%2BD1cXpt1Sgsrw%3D This is an excellent review of high-grade gliomas, including molecular biology and treatment
4. J Clarke N Butowski S Chang 2010 Recent advances in therapy for glioblastoma Arch Neurol 67 3 279 83 20212224 10.1001/archneurol.2010.5
5. M Lacroix D Abi-Said DR Fourney, et al. 2001 A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival J Neurosurg 95 2 190 8 11780887 10.3171/jns.2001.95.2.0190 1:STN:280:DC%2BD38%2FlsFGitA%3D%3D (Pubitemid 32799739)
6. U Pichlmeier A Bink G Schackert ALA Glioma Study Group, et al. 2008 Resection and survival in glioblastoma multiforme: an RTOG recursive partitioning analysis of ALA study patients Neuro Oncol 10 6 1025 34 18667747 10.1215/15228517-2008-052 This randomized trial demonstrated a benefit for a fluorescent-labeled marker to increase the rate of complete resection in glioblastoma; complete resection was associated with superior survival regardless of other treatments
7. A Narayana J Yamada S Berry, et al. 2006 Intensity-modulated radiotherapy in high-grade gliomas: clinical and dosimetric results Int J Radiat Oncol Biol Phys 64 3 892 7 16458777 10.1016/j.ijrobp.2005.05.067 (Pubitemid 43183590)
8. R Stupp WP Mason MJ van den Bent, et al. 2005 Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Engl J Med 352 987 96 15758009 10.1056/NEJMoa043330 1:CAS:528:DC%2BD2MXit1Wksbk%3D (Pubitemid 40349501)
9. H Yan DW Parsons G Jin, et al. 2009 IDH1 and IDH2 mutations in gliomas N Engl J Med 360 8 765 73 19228619 10.1056/NEJMoa0808710 1:CAS:528: DC%2BD1MXitFWru7o%3D This study evaluated IDH1 and IDH2 mutations as important molecular markers in patients with anaplastic oligodendroglial and astrocytic tumors as well as secondary glioblastoma
10. LA Stewart 2002 Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials Lancet 359 1011 8 11937180 10.1016/S0140-6736(02)08091-1 1:CAS:528: DC%2BD38XisV2htro%3D (Pubitemid 34286538)
11. R Stupp ME Hegi WP Mason European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group, et al. 2009 Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial Lancet Oncol 10 5 459 66 19269895 10.1016/S1470-2045(09)70025-7 1:CAS:528:DC%2BD1MXlsVKhs74%3D This analysis of the original EORTC trial shows a statistically significant benefit at 5 years for patients treated with concurrent and adjuvant temozolomide
12. R Stupp ME Hegi MR Gilbert A Chakravarti 2007 Chemoradiotherapy in malignant glioma: standard of care and future directions J Clin Oncol 25 26 4127 36 17827463 10.1200/JCO.2007.11.8554 1:CAS:528:DC%2BD2sXhtlKqsbrE (Pubitemid 47492957)
13. ME Hegi AC Diserens T Gorlia, et al. 2005 MGMT gene silencing and benefit from temozolomide in glioblastoma N Engl J Med 352 10 997 1003 15758010 10.1056/NEJMoa043331 1:CAS:528:DC%2BD2MXit1Wktro%3D (Pubitemid 40349502)
14. AL Rivera CE Pelloski MR Gilbert, et al. 2010 MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma Neuro Oncol 12 2 116 21 20150378 1:CAS:528:DC%2BC3cXotFKitb8%3D
15. AA Brandes E Franceschi A Tosoni, et al. 2008 MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients J Clin Oncol 26 13 219 27 10.1200/JCO.2007.14.8163
16. AA Brandes A Tosoni E Franceschi, et al. 2009 Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation with MGMT promoter methylation status J Clin Oncol 27 8 1275 9 19188675 10.1200/JCO.2008.19.4969 1:CAS:528: DC%2BD1MXktFKhsb4%3D
17. W Wick M Platten M Weller 2009 New (alternative) temozolomide regimens for the treatment of glioma Neuro Oncol 11 1 69 79 18772354 10.1215/15228517- 2008-078 1:CAS:528:DC%2BD1MXjtFKntr8%3D
18. JL Clarke FM Iwamoto J Sul, et al. 2009 Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma J Clin Oncol 27 23 3861 7 19506159 10.1200/JCO.2008.20.7944 1:CAS:528:DC%2BD1MXhtFaitrrJ
19. M Glas C Happold J Rieger, et al. 2009 Long-term survival of patients with glioblastoma treated with radiotherapy and lomustine plus temozolomide J Clin Oncol 27 8 1257 61 19188676 10.1200/JCO.2008.19.2195 1:CAS:528: DC%2BD1MXktFKhsLk%3D
20. M Westphal Z Ram V Riddle, et al. 2006 Gliadel wafer in initial surgery for malignant glioma: long-term follow-up of a multi-center controlled trial Acta Neurochir (Wien) 148 269 75 10.1007/s00701-005-0707-z 1:STN:280: DC%2BD28znvFWmtQ%3D%3D
21. HC Bock MJ Puchner F Lohmann, et al. 2010 First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a multicenter experience Neurosurg Rev 33 4 441 9 20706757 10.1007/s10143-010-0280-7
22. ML Affronti CR Heery JE Herndon 2nd, et al. 2009 Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy Cancer 115 15 3501 11 19514083 10.1002/cncr.24398 1:CAS:528:DC%2BD1MXpslOnurw%3D
23. PC De Witt Hamer 2010 Small molecule kinase inhibitors in glioblastoma: a systematic review of clinical studies Neuro Oncol 12 3 304 16 20167819
24. MD Prados SM Chang N Butowski, et al. 2009 Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma J Clin Oncol 27 4 579 84 19075262 10.1200/JCO.2008.18.9639 1:CAS:528:DC%2BD1MXivFyjurk%3D
25. DM Peereboom DR Shepard MS Ahluwalia, et al. 2010 Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme J Neurooncol 98 1 93 9 19960228 10.1007/s11060-009-0067- 2 1:CAS:528:DC%2BC3cXntVClu74%3D
26. R Stupp ME Hegi B Neyns, et al. 2010 Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma J Clin Oncol 28 16 2712 8 20439646 10.1200/JCO.2009.26.6650 1:CAS:528: DC%2BC3cXoslyktLs%3D
27. SA Grossman X Ye M Chamberlain, et al. 2009 Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: a multicenter phase II trial J Clin Oncol 27 25 4155 61 19636006 10.1200/JCO.2008.21.6895 1:CAS:528:DC%2BD1MXhtF2jtLrI
28. SA Grossman X Ye S Piantadosi NABTT CNS Consortium, et al. 2010 Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States Clin Cancer Res. 16 8 2443 9 20371685 10.1158/1078-0432.CCR-09-3106 1:CAS:528:DC%2BC3cXkslSlsb4%3D
29. JG Cairncross K Ueki MC Zlatescu, et al. 1998 Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas J Natl Cancer Inst 90 1473 9 9776413 10.1093/jnci/90.19.1473 1:STN:280:DyaK1cvkslejug%3D%3D (Pubitemid 28482012)
30. W Wick C Hartmann C Engel, et al. 2009 NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide J Clin Oncol 27 35 5874 80 19901110 10.1200/JCO.2009.23.6497 1:CAS:528:DC%2BC3cXhtVWis7g%3D This trial showed equivalence of radiotherapy followed by chemotherapy versus chemotherapy followed by radiotherapy in patients with anaplastic gliomas. It also showed equivalence and less toxicity of temozolomide versus PCV chemotherapy
31. MJ van den Bent HJ Dubbink M Sanson, et al. 2009 MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951 J Clin Oncol 27 35 5881 6 19901104 10.1200/JCO.2009.24. 1034
32. Intergroup Radiation Therapy Oncology Group Trial 9402 G Cairncross B Berkey E Shaw, et al. 2006 Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402 J Clin Oncol 24 18 2707 14 16782910 10.1200/JCO.2005.04.3414 1:CAS:528: DC%2BD28XntV2hurg%3D (Pubitemid 46630566)
33. MJ van den Bent AF Carpentier AA Brandes, et al. 2006 Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial J Clin Oncol 24 18 2715 22 16782911 10.1200/JCO.2005.04.6078 (Pubitemid 46630567)
34. LE Abrey DN Louis N Paleologos Oligodendroglioma Study Group, et al. 2007 Survey of treatment recommendations for anaplastic oligodendroglioma Neuro Oncol 9 3 314 8 17435180 10.1215/15228517-2007-002 1:CAS:528: DC%2BD2sXpt1agtr8%3D (Pubitemid 47169664)
35. R Mayer P Sminia 2008 Reirradiation tolerance of the human brain Int J Radiat Oncol Biol Phys 70 5 1350 60 18037587 10.1016/j.ijrobp.2007.08.015 1:CAS:528:DC%2BD1cXktVChtrs%3D (Pubitemid 351417752)
36. PY Wen DR Macdonald DA Reardon, et al. 2010 Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group J Clin Oncol 28 11 1963 72 20231676 10.1200/JCO.2009.26.3541
37. FM Iwamoto HA Fine 2010 Bevacizumab for malignant gliomas Arch Neurol 67 3 285 8 20212225 10.1001/archneurol.2010.11
38. AD Norden J Drappatz PY Wen 2009 Antiangiogenic therapies for high-grade glioma Nat Rev Neurol 5 11 610 20 19826401 10.1038/nrneurol.2009.159 1:CAS:528:DC%2BD1MXhtlKhtLbE
39. JJ Vredenburgh A Desjardins JE Herndon 2nd, et al. 2007 Bevacizumab plus irinotecan in recurrent glioblastoma multiforme J Clin Oncol 25 30 4722 9 17947719 10.1200/JCO.2007.12.2440 1:CAS:528:DC%2BD2sXhtlCgsLjF (Pubitemid 350086473)
40. A Desjardins DA Reardon JE Herndon 2nd, et al. 2008 Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas Clin Cancer Res 14 21 7068 73 18981004 10.1158/1078-0432.CCR-08-0260 1:CAS:528:DC%2BD1cXhtlens7fJ
41. HS Friedman MD Prados PY Wen, et al. 2009 Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma J Clin Oncol 27 28 4733 40 19720927 10.1200/JCO.2008.19.8721 1:CAS:528:DC%2BD1MXhtlGgtbbM This trial confirmed the effect on PFS of bevacizumab in recurrent glioblastoma and supported its accelerated FDA approval in 2009
42. TN Kreisl L Kim K Moore, et al. 2009 Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma J Clin Oncol 27 5 740 5 19114704 10.1200/JCO.2008.16.3055 1:CAS:528:DC%2BD1MXjsVCjs7o%3D This trial confirmed the effect on PFS of bevacizumab in recurrent glioblastoma and supported its accelerated FDA approval in 2009
43. TT Batchelor DG Duda E di Tomaso, et al. 2010 Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma J Clin Oncol 28 17 2817 23 20458050 10.1200/JCO.2009.26.3988 1:CAS:528:DC%2BC3cXptFKmu78%3D
44. M Pàez-Ribes E Allen J Hudock, et al. 2009 Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis Cancer Cell 15 3 220 31 19249680 10.1016/j.ccr.2009.01.027
45. AD Norden GS Young K Setayesh, et al. 2008 Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence Neurology 70 10 779 87 18316689 10.1212/01.wnl.0000304121.57857.38 1:CAS:528: DC%2BD1cXitlyqs7o%3D
46. FM Iwamoto LE Abrey K Beal, et al. 2009 Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma Neurology 73 15 1200 6 19822869 10.1212/WNL.0b013e3181bc0184 1:CAS:528:DC%2BD1MXht1antrfK
47. Levin VA, Bidaut L, Hou P, et al. Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. Int J Radiat Oncol Biol Phys. 2010 Apr 15 (Epub ahead of print). This trial demonstrated a clear benefit of bevacizumab in treating radiation necrosis in the CNS.
48. JR Perry K Bélanger WP Mason, et al. 2010 Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study J Clin Oncol 28 12 2051 7 20308655 10.1200/JCO.2009.26.5520 1:CAS:528:DC%2BC3cXmtlSksrk%3D
49. DS Kong JI Lee JH Kim, et al. 2010 Phase II trial of low-dose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma Neuro Oncol 12 3 289 96 20167817 1:CAS:528:DC%2BC3cXot1Gmurg%3D
50. 6-benzylguanine in adults with recurrent, temozolomide- resistant malignant glioma J Clin Oncol 27 8 1262 7 19204199 10.1200/JCO.2008.18.8417 1:CAS:528:DC%2BD1MXktFKhsLY%3D